CN112755143A - Traditional Chinese medicine composition for treating eczema and application thereof - Google Patents
Traditional Chinese medicine composition for treating eczema and application thereof Download PDFInfo
- Publication number
- CN112755143A CN112755143A CN202110225033.6A CN202110225033A CN112755143A CN 112755143 A CN112755143 A CN 112755143A CN 202110225033 A CN202110225033 A CN 202110225033A CN 112755143 A CN112755143 A CN 112755143A
- Authority
- CN
- China
- Prior art keywords
- parts
- eczema
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 54
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 43
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 36
- 208000003251 Pruritus Diseases 0.000 claims abstract description 29
- 230000001154 acute effect Effects 0.000 claims abstract description 28
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 20
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 20
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 20
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 20
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 20
- 239000006002 Pepper Substances 0.000 claims abstract description 20
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 20
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 20
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 244000207740 Lemna minor Species 0.000 claims abstract description 18
- 235000006439 Lemna minor Nutrition 0.000 claims abstract description 18
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 17
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 17
- 240000000249 Morus alba Species 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 17
- 240000000233 Melia azedarach Species 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 6
- 229940040145 liniment Drugs 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004576 sand Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 241000722363 Piper Species 0.000 claims 3
- 239000006208 topical dosage form Substances 0.000 claims 1
- 230000007803 itching Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 240000003889 Piper guineense Species 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010037844 rash Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- -1 sucrose ester Chemical class 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- 244000301850 Cupressus sempervirens Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000007853 Sarothamnus scoparius Species 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229940106705 chlorophyll Drugs 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating eczema and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-30 parts of folium artemisiae argyi, 30-60 parts of radix sophorae flavescentis, 4-9 parts of mint, 10-15 parts of wild chrysanthemum flower, 9-15 parts of radix stemonae, 9-15 parts of szechwan chinaberry fruit, 12-18 parts of spreading hedyotis herb, 9-15 parts of cortex dictamni, 6-12 parts of duckweed, 6-12 parts of pepper, 12-15 parts of mulberry leaf, 12-15 parts of fructus kochiae, 12-15 parts of honeysuckle flower and 15-30 parts of honeysuckle stem. The invention also comprises the application of the traditional Chinese medicine composition in preparing a medicine for treating eczema. Its advantages are: the raw material medicines and the weight part ratio thereof are optimized, the curative effect on treating acute eczema and large skin itching area caused by acute attack of chronic eczema is excellent, especially on children skin eczema, and the traditional Chinese medicine composition can be well applied to clinic.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating eczema and application thereof.
Background
Eczema is a skin inflammatory reaction with severe pruritus caused by various internal and external factors and is divided into three stages of acute stage, subacute stage and chronic stage. The acute stage is prone to exudation, while the chronic stage is infiltrative and hypertrophic. Some patients directly manifest chronic eczema. The skin lesion has the characteristics of polymorphism, symmetry, pruritus, easy repeated attack and the like. Eczema is a complex etiology, often resulting from the interaction of internal and external factors. Internal factors such as chronic digestive system diseases, mental stress, insomnia, overfatigue, mood changes, endocrine dyscrasia, infection, metabolism disorder and the like, and external factors such as living environment, climate changes, food and the like can influence the occurrence of eczema. External stimuli such as sunlight, cold, dryness, heat, hot water scald and washing, as well as various animal skins, plants, cosmetics, soaps, artificial fibers and the like can induce, and are a delayed allergic reaction caused by complicated internal and external factors.
Common acute eczema is skin inflammation with polymorphous rash and exudation tendency, accompanied by severe pruritus and easy recurrence. Acute eczema can occur in any part of the body, but is often easily seen in the head, the bent sides of the limbs, the pudendum, the dorsum of the hands and feet, and the like. They are usually distributed symmetrically and usually confined to some parts, but generalized eczema is rare. Skin lesions are characterized by polymorphism, i.e., erythema, papules, blisters, erosion, exudation, crusting, desquamation, and other forms of skin rash are seen in each other. The inflammatory reaction of the affected part is usually obvious, particularly the central part is more obvious and is often accompanied with erosion and exudation, but the disease damage boundary is not clear, the swelling is light, the subjective itching is severe, and the degree of the itching is different from the tolerance of the affected part and the individual. Itching is especially acute at night, and severe symptoms can affect sleep. And suppurative skin diseases such as folliculitis, furuncle, impetigo, lymphangitis, lymphadenitis and the like are caused by easy bacterial infection due to pruritus. Currently, most western medicines are treated by oral antihistamine medicines. Such as diphenhydramine, finasteride, chlorpheniramine, cyproheptadine, etc., can be used alone or in combination, or can be used in combination with sedative and vitamin C to improve therapeutic effect. The dosage form for external use is determined according to clinical skin damage, if the red swelling is obvious, the exudation is large, the solution should be selected for cold and wet compress, and lotion, emulsion, paste, oil agent and the like can be used for erythema and pimple; oil solution is needed for blister and erosion. Acute eczema is treated properly, so that inflammation is relieved, skin damage can be relieved after 2-3 weeks, but the acute eczema frequently occurs repeatedly and can be converted into subacute or chronic eczema.
In the period that acute eczema of infants is frequently found in infants at 0-2 years old, the infants commonly suffer from diseases in the first and second february after birth and also frequently suffer from diseases in the second and third months of life, the inflammation of the superficial dermis and epidermis caused by various internal and external factors is generally considered to be related to allergic reaction, the rash of the infants has polymorphism, is symmetrically distributed, is easy to exude, repeatedly attacks, and has spontaneous pruritus, is easy to develop into chronic, and has the characteristic of no scar left after healing. Therefore, the search for a medicine which can effectively treat skin pruritus caused by acute eczema or acute attack of chronic eczema is urgent. The invention provides a medicine for effectively treating the disease aiming at the defect, and the traditional Chinese medicine composition for treating eczema and the application thereof are not reported at present.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating eczema and application thereof, aiming at the defects of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
in a first aspect, the invention provides a traditional Chinese medicine composition for treating eczema, which comprises the following raw material medicines in parts by weight: 20-30 parts of folium artemisiae argyi, 30-60 parts of radix sophorae flavescentis, 4-9 parts of mint, 10-15 parts of wild chrysanthemum flower, 9-15 parts of radix stemonae, 9-15 parts of szechwan chinaberry fruit, 12-18 parts of spreading hedyotis herb, 9-15 parts of cortex dictamni, 6-12 parts of duckweed, 6-12 parts of pepper, 12-15 parts of mulberry leaf, 12-15 parts of fructus kochiae, 12-15 parts of honeysuckle flower and 15-30 parts of honeysuckle stem.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 25-30 parts of folium artemisiae argyi, 40-60 parts of radix sophorae flavescentis, 6-9 parts of mint, 12-15 parts of wild chrysanthemum flower, 12-15 parts of radix stemonae, 9-12 parts of szechwan chinaberry fruit, 12-15 parts of spreading hedyotis herb, 12-15 parts of cortex dictamni, 6-10 parts of duckweed, 6-10 parts of pepper, 13-15 parts of mulberry leaf, 13-15 parts of fructus kochiae, 13-15 parts of honeysuckle flower and 25-30 parts of honeysuckle stem.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 30 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 6 parts of mint, 15 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 6 parts of duckweed, 6 parts of pepper, 15 parts of mulberry leaf, 15 parts of fructus kochiae, 15 parts of honeysuckle flower and 30 parts of honeysuckle stem.
Further, the traditional Chinese medicine composition also comprises a pharmaceutically acceptable carrier.
Furthermore, the traditional Chinese medicine composition is a clinically acceptable external preparation.
Preferably, the external dosage form comprises a spray, a liniment, an ointment, a lotion or a patch.
In a second aspect, the invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating eczema.
Furthermore, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating skin itch caused by acute eczema and/or acute attack of chronic eczema.
Furthermore, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating skin itch caused by acute eczema of children and/or acute attack of chronic eczema of children.
In a third aspect, the invention provides a lotion for treating eczema, which is prepared from the traditional Chinese medicine composition, and the preparation method of the lotion comprises the following steps:
(1) taking the raw materials according to the weight part ratio, cleaning, putting into an automatic purple sand traditional Chinese medicine decocting pot, adding water, soaking over strong fire, and decocting for 0.5-1 hour;
(2) decocting with slow fire for 15-20 min;
(3) removing residue, filtering, and decocting in water for 1 time;
(4) mixing the filtrates, and cooling to 38-44 deg.C.
Square solution:
the etiology is as follows: eczema is caused by congenital and acquired factors, and internal factors such as improper diet damage to spleen and stomach, wind, dampness and heat cause heart, liver, spleen and lung to be affected by exposure to sensitizing substances. The treatment mainly aims at dispelling wind and eliminating dampness, clearing heat and detoxicating and relieving itching, and moistening dryness. In the formula, the folium artemisiae argyi and the radix sophorae flavescentis are used for removing dampness and relieving itching, and are used as monarch drugs in large amount; radix stemonae, pepper and raw toosendan fruit are used for killing parasites and relieving itching, cortex dictamni and broom cypress fruit are used for clearing heat, promoting diuresis, dispelling wind and relieving itching, and spreading hedyotis herb and honeysuckle flower are used as ministerial medicines for clearing heat and removing toxicity; the honeysuckle stem is used for dispelling wind and dredging collaterals, is matched with duckweed for dispersing and promoting eruption, inducing diuresis for removing edema, eliminating pathogenic factors from urine, and is used as an adjuvant drug together with mulberry leaves for dispelling wind, clearing heat and moistening dryness, mint for dispelling wind heat, and the cool property of the mint for dispelling wind and restricting the warm and dry property of the pepper and the folium artemisiae argyi.
The compatibility is characterized in that: the formula combines cold and warm, moistens dryness and supplements each other, and combines the medicines to play the main roles of dispelling wind and removing dampness, clearing heat and detoxicating and relieving itching and moisten dryness.
Term(s) for
As used herein, an ingredient of the term "pharmaceutically acceptable" is one that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), i.e., at a reasonable benefit/risk ratio.
As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents and the like. The term refers to such pharmaceutical carriers: they are not essential active ingredients per se and are not unduly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A thorough discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences (mackpub.co., n.j.1991). Pharmaceutically acceptable carriers in the compositions may comprise liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as emulsifiers, fillers, binders, wetting agents, disintegrants, absorption enhancers, flavoring agents, colorants, cosolvents and the like may also be present in these carriers. The emulsifier is selected from acetylated monoglyceride, acetylated diglyceride, sucrose ester, sorbitol ester, soybean phospholipid, lauric monoglyceride, propylene glycol fatty acid ester, calcium stearoyl lactylate, diacetyl tartaric acid, glyceryl monostearate, modified soybean phospholipid, etc. Such as magnesium stearate, microcrystalline cellulose, lactose, milk sugar, high molecular weight polyethylene glycols, and the like. Such as starch, mannitol, silicic acid, dextrin, calcium hydrogen phosphate, cellulose, etc. Such as carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, gum arabic, starch slurry, hydroxypropyl starch, modified starch, pregelatinized starch, dextrin, microcrystalline cellulose, polyvinyl pyrrolidone mucilage, gelatin mucilage. Such as glycerin and the like. The disintegrating agent is agar, calcium carbonate, potato starch, tapioca starch, alginic acid, hydroxypropyl starch, modified starch, sodium carboxymethyl starch, microcrystalline cellulose, guar gum, xanthan gum, etc. The absorption enhancer is such as quaternary ammonium compound, effervescent agent, cyclodextrin, vitamin D and its derivatives, piperine, etc. The flavoring agent can be sour agent, sweetener, such as phosphoric acid, lactic acid, tartaric acid, malic acid, fumaric acid, acetic acid, succinic acid, xylitol, steviosin, sodium cyclamate, aspartame, oleum Menthae Dementholatum, etc. The colorant may be a plant colorant, an animal colorant or a microbial colorant, such as beet red, turmeric, chlorophyll, shellac, cochineal, red yeast colorant, and the like. Such as beta-cyclodextrin, maltodextrin, tween, ethanol, span, sodium dodecyl sulfate, propylene glycol, polyethylene glycol, glycerol, etc. However, it will be appreciated by those skilled in the art that the pharmaceutically acceptable carriers useful in the present invention are not limited to the above-mentioned types.
As used herein, "parts by weight" can be any fixed weight expressed in milligrams, grams, or kilograms (e.g., 1mg, 1g, 2g, 5g, or 1kg, etc.). For example, a composition consisting of 1 part by weight of component a and 9 parts by weight of component b may be a composition consisting of 1g of component a +9 g of component b, or 10 g of component a +90 g of component b. In the composition, the percentage content of a certain component is (parts by weight of the component/sum of parts by weight of all components) × 100%. Thus, in a composition consisting of 1 part by weight of component a and 9 parts by weight of component b, the content of component a is 10% and component b is 90%.
Dosage forms
The dosage form of the traditional Chinese medicine composition is not particularly limited, and can be any dosage form suitable for being taken by mammals; preferably, the dosage form may be selected from: spray, liniment, paste, lotion or patch.
The composition of the invention can be added with various conventional carriers or auxiliary materials required by preparing different dosage forms, such as filler (such as starch), flavoring agent (such as steviosin), antioxidant or coating material, and the like. Can be prepared into any common dosage form by conventional Chinese medicinal preparation method, such as spray, liniment, unguent, lotion or patch.
Preparation method
After knowing the raw materials and their formulation used in the Chinese medicinal composition of the present invention, those skilled in the art can use various conventional methods to process the raw materials into drugs. Such processing includes, but is not limited to: pulverizing, extracting with water, extracting with organic solvent, etc. More specifically, the process comprises, for example, the steps of: weighing, pulverizing, decocting, etc.
The raw materials can be mixed and then the effective components are extracted by a proper method to prepare the traditional Chinese medicine composition; in addition, the effective components can also be extracted respectively (for example, the same or different extraction or processing methods are adopted respectively) and then combined to prepare the traditional Chinese medicine composition.
In addition, the technicians in the field can also directly adopt the effective parts of the raw material medicines for processing so as to prepare the traditional Chinese medicine composition. Furthermore, those skilled in the art can extract active ingredients from the raw materials, mix and process the active ingredients to prepare the traditional Chinese medicine composition.
Optionally, other pharmaceutically (or dietetically or nutraceutically) acceptable carriers can be added during the preparation process.
Use and method of use
The traditional Chinese medicine composition can be directly used for treating acute eczema and skin pruritus caused by acute attack of chronic eczema. The traditional Chinese medicine composition can also contain other optional medicinal materials or medicinal material extracts.
The amount of the Chinese medicinal composition of the present invention to be used may vary depending on the mode of administration, the dosage form and the severity of the disease to be treated. For example, a single dose may be administered several times daily in divided doses, or the dose may be reduced proportionally as required by the condition being treated. Of course, the particular dosage will also take into account such factors as the mode of administration, the physical condition of the subject being administered, and the like, which are within the skill of the art.
The invention has the advantages that:
1. the traditional Chinese medicine composition is prepared by optimally selecting raw materials and the weight part ratio thereof according to the etiology and pathogenesis of acute eczema, combining cold and warm in the whole formula, taking the functions of dispelling wind and removing dampness, clearing heat and removing toxicity and relieving itching as the treatment principle, and taking folium artemisiae argyi and radix sophorae flavescentis as the prescription for removing dampness and relieving itching, wherein the traditional Chinese medicine composition is a monarch drug with large dosage; radix stemonae, pepper and raw toosendan fruit are used for killing parasites and relieving itching, cortex dictamni and broom cypress fruit are used for clearing heat, promoting diuresis, dispelling wind and relieving itching, and spreading hedyotis herb and honeysuckle flower are used as ministerial medicines for clearing heat and removing toxicity; the honeysuckle stem has the effects of dispelling wind and dredging collaterals, is matched with duckweed for dispersing and promoting eruption, inducing diuresis for removing edema, discharging evil from urine, folium mori for dispelling wind, clearing heat and moistening dryness, mint for dispelling wind and heat, and the cooling property of the mint for dispelling wind and removing dampness, and the property of the folium mori for restricting the warm and dry properties of the pepper and the folium artemisiae argyi, and is used as an adjuvant with the wild chrysanthemum flower, so that the cold and warm components of the whole formula are combined, the dryness is relieved, the medicines are combined to play a role of dispelling wind and removing dampness, the heat and detoxifying for relieving itching, and the dryness is relieved.
2. The traditional Chinese medicine composition has no obvious adverse reaction or complication, and is safe and reliable.
3. The traditional Chinese medicine composition can be prepared into different formulations according to the convenience of patients or the requirements, is suitable for being prepared into a commercial compound preparation, is convenient to accept, and has wide application prospect.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
EXAMPLE 1 Chinese medicinal composition 1
20 parts of folium artemisiae argyi, 30 parts of radix sophorae flavescentis, 4 parts of mint, 10 parts of wild chrysanthemum flower, 9 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 9 parts of cortex dictamni, 6 parts of duckweed, 6 parts of pepper, 12 parts of mulberry leaf, 12 parts of fructus kochiae, 12 parts of honeysuckle flower and 15 parts of honeysuckle stem.
EXAMPLE 2 Chinese medicinal composition (II)
30 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 9 parts of mint, 15 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 15 parts of szechwan chinaberry fruit, 18 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 12 parts of duckweed, 12 parts of pepper, 15 parts of mulberry leaf, 15 parts of fructus kochiae, 15 parts of honeysuckle flower and 30 parts of honeysuckle stem.
EXAMPLE 3 Chinese medicinal composition (III)
20 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 4 parts of mint, 15 parts of wild chrysanthemum flower, 9 parts of radix stemonae, 15 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 6 parts of duckweed, 12 parts of pepper, 12 parts of mulberry leaf, 15 parts of fructus kochiae, 12 parts of honeysuckle flower and 30 parts of honeysuckle stem.
EXAMPLE 4 Chinese medicinal composition (IV)
30 parts of folium artemisiae argyi, 30 parts of radix sophorae flavescentis, 9 parts of mint, 10 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 18 parts of spreading hedyotis herb, 9 parts of cortex dictamni, 12 parts of duckweed, 6 parts of pepper, 15 parts of mulberry leaf, 12 parts of fructus kochiae, 15 parts of honeysuckle flower and 15 parts of honeysuckle stem.
EXAMPLE 5 Chinese medicinal composition (V)
25 parts of folium artemisiae argyi, 40 parts of radix sophorae flavescentis, 6 parts of mint, 12 parts of wild chrysanthemum flower, 12 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 12 parts of cortex dictamni, 6 parts of duckweed, 6 parts of pepper, 13 parts of mulberry leaf, 13 parts of fructus kochiae, 13 parts of honeysuckle flower and 25 parts of honeysuckle stem.
EXAMPLE 6 Chinese medicinal composition (VI)
30 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 9 parts of mint, 15 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 12 parts of szechwan chinaberry fruit, 15 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 10 parts of duckweed, 10 parts of pepper, 15 parts of mulberry leaf, 15 parts of fructus kochiae, 15 parts of honeysuckle flower and 30 parts of honeysuckle stem.
EXAMPLE 7 Chinese medicinal composition (seven)
25 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 6 parts of mint, 15 parts of wild chrysanthemum flower, 12 parts of radix stemonae, 12 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 6 parts of duckweed, 10 parts of pepper, 13 parts of mulberry leaf, 15 parts of fructus kochiae, 13 parts of honeysuckle flower and 30 parts of honeysuckle stem.
EXAMPLE 8 Chinese medicinal composition (eight)
30 parts of folium artemisiae argyi, 40 parts of radix sophorae flavescentis, 9 parts of mint, 12 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 15 parts of spreading hedyotis herb, 12 parts of cortex dictamni, 10 parts of duckweed, 6 parts of pepper, 15 parts of mulberry leaf, 13 parts of fructus kochiae, 15 parts of honeysuckle flower and 25 parts of honeysuckle stem.
EXAMPLE 9 Chinese medicinal composition (nine)
30 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 6 parts of mint, 15 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 6 parts of duckweed, 6 parts of pepper, 15 parts of mulberry leaf, 15 parts of fructus kochiae, 15 parts of honeysuckle flower and 30 parts of honeysuckle stem.
Example 10 lotion
The preparation method comprises the following steps:
taking the raw materials in any one of the embodiments 1-9 according to the weight part ratio, cleaning, putting into an automatic purple sand traditional Chinese medicine decocting pot, adding cold water, decocting with strong fire, and soaking for 0.5-1 hour; decocting with slow fire for 15-20 min; removing residue, filtering, and decocting in water for 1 time; mixing the filtrates, and cooling to 38-44 deg.C.
EXAMPLE 11 Liniment
The preparation method comprises the following steps:
the raw materials in the weight parts of any one of the embodiments 1-9 are respectively crushed into fine powder and then mixed or crushed into fine powder after being mixed, and the fine powder is sieved by a 400-mesh sieve for later use; and adding conventional adjuvants into the fine powder, and making into clinically acceptable liniment by conventional method.
Example 12 paste
The preparation method comprises the following steps:
taking the raw materials in any one of the embodiments 1-9 according to the weight part ratio, cleaning, putting into an automatic purple sand traditional Chinese medicine decocting pot, adding cold water, decocting with strong fire, and soaking for 0.5-1 hour; decocting with slow fire for 15-20 min; removing residue, filtering, and decocting in water for 1 time; mixing the filtrates, standing overnight, collecting supernatant, and concentrating to obtain extract with relative density of 1.1-1.2 at 60 deg.C; and (3) adding conventional auxiliary materials into the extract to prepare clinically acceptable paste according to a conventional process.
Example 13 Patch preparation
The preparation method comprises the following steps:
taking the raw materials in any one of the embodiments 1-9 according to the weight part ratio, cleaning, putting into an automatic purple sand traditional Chinese medicine decocting pot, adding cold water, decocting with strong fire, and soaking for 0.5-1 hour; decocting with slow fire for 15-20 min; removing residue, filtering, and decocting in water for 1 time; mixing the filtrates, standing overnight, collecting supernatant, and concentrating to obtain extract with relative density of 1.1-1.2 at 60 deg.C; and (3) adding conventional auxiliary materials into the extract to prepare a clinically acceptable patch according to a conventional process.
Example 14 acute toxicity test
Taking 50 Kunming mice with half each male and female, the weight of 18-22 g, immediately dividing into 5 groups, 10 mice in each group, wherein 4 groups are separately intragastrically filled with the medicament prepared in the invention from the embodiment 1 to the embodiment 4, the intragastrically filled amount is 22 ml/(kg. d), the contrast group is intragastrically filled with distilled water, the intragastrically filled amount is 40ml/kg, 1 time respectively in the morning, the noon and the evening, and the reaction conditions of the animals are immediately observed after administration, including the appearance, behavior, mental state, appetite, excrement and urine, color, fur, nose, eyes, mouth, abnormal secretion and death conditions. And observing every 30min to 1h for 1 time on the 1 st day of administration, observing and weighing the body weight for 1 time every day, continuously observing for 14d, and recording animal toxicity reaction and death distribution condition as body weight change and reaction condition. The results show that the mice had normal activities, food intake, excretion, good growth, bright hair color, weight gain, and no death within 14d after the administration, so no LD50 was detected. The average body weight thereof increased with the lapse of the test time, and was the same as that of the control group at the corresponding time. At the end of the observation period, the dead animal bodies are sacrificed and observed by naked eyes, and the mice of the administration group and the control group have no abnormal change of organs.
Example 15 Long term toxicity test
50 guinea pigs are selected, male and female halves are selected, the weight is 250 g-300 g, the guinea pigs are divided into 5 groups, each group comprises 10 guinea pigs, wherein 1 group of guinea pigs is a blank control group, and 4 groups of guinea pigs are respectively drenched with the medicament prepared in the invention in the embodiments 1-4, the stomach irrigation amount is 52 ml/(kg. d), 90 days are continuously carried out, the blank control group is given with equal amount of distilled water, the appearance and the behavior of animals are observed in the experiment, the weight is recorded, and after the administration of the medicament and fasting for 12 hours on the 90 th day, the routine examination of blood and urine and feces and the serum SGPT and BUN determination are carried out. Finally, the animals are killed by the 3% sodium pentobarbital in an excessive anesthesia mode, and the heart, the liver and the kidney are picked up for pathological examination, and the result shows that the observation indexes are not abnormally changed or the animals die. And (4) visual observation: the pleuroperitoneal cavity has no blood leakage, and the color, the size, the shape and the like of the organ administration group of heart, liver, kidney and the like have no obvious difference compared with the control group. And (3) histological observation: the tissue structures of the heart, the liver and the kidney of each group are normal, and no obvious pathological change is found compared with a control group.
EXAMPLE 16 clinical trial one
1 data of
1.1 general data
103 patients suffering from skin eczema, who are diagnosed in Jinshan Hospital affiliated to the university of Fudan in 2018, 6-2020 and 5, are selected and divided into three groups according to a random digital table method, wherein the three groups are respectively an experimental group, a control group and a control group, and the patients in each group have no significant difference in aspects of sex, age, course of disease and the like before treatment, and have good balance among the groups and comparability.
1.2 inclusion criteria
The age of the tea is 18-50 years old.
Secondly, the medicine accords with the acute eczema diagnosis standard in skin pathology (published by the national health publisher, 2002) and traditional Chinese medicine syndrome diagnosis curative effect standard issued by the national traditional Chinese medicine administration (published by 1994);
and thirdly, other medicines for treating acute eczema are not used before.
1.3 criteria for shedding
(1) Incomplete data will affect the final statistical data result.
(2) After inclusion, the false-selected person is found to be not in accordance with the inclusion standard, or the person in accordance with the exclusion standard.
2 method
2.1 methods of treatment
Experimental groups: the traditional Chinese medicine composition in the embodiment 9 is prepared into paste twice a day, 2-3 weeks are a treatment course, and the dosage of the medicine is reduced as appropriate for patients with small eczema.
Control group: applying the pimpines ointment externally for 3 times/d, 7 days for 1 treatment course, and 2 treatment courses in total.
Control two groups: the traditional Chinese medicine composition is used: 25 parts of folium artemisiae argyi, 65 parts of radix sophorae flavescentis, 10 parts of cortex phellodendri, 10 parts of rhizoma atractylodis, 10 parts of oldenlandia diffusa, 15 parts of dendrobe, 5 parts of codonopsis pilosula, 10 parts of radix sileris and 10 parts of gallnut. The ointment is prepared twice a day, 2-3 weeks are a treatment course, and the dosage of the medicine is reduced as appropriate for patients with small eczema area.
2.2 therapeutic efficacy assessment criteria
According to the curative effect standard of acute eczema in the 'traditional Chinese medicine disease diagnosis curative effect standard' issued by the State administration of traditional Chinese medicine:
(1) and (3) healing: the rash is completely removed without itching feeling;
(2) the effect is shown: the rash subsides by more than 60 percent and has slight itching feeling;
(3) the method has the following advantages: the rash subsides by 20-60%, and the itching feeling is slightly relieved;
(4) and (4) invalidation: the symptoms are unchanged compared with the symptoms before treatment, and the skin damage is expanded.
3 results
The results of the treatment effect and the recurrence rate of each group are shown in Table 1.
TABLE 1 curative effect and recurrence rate of each group
Toxic and side effects: after the treatment of the experimental group, the hematuria routine, the stool, the heart, the liver and the kidney function are rechecked, and no abnormality is found. The above cases were revisited after 3 months without recurrence. The experimental group has significant difference in total effective rate and recurrence rate compared with the control group and the control group.
EXAMPLE 17 clinical trial (two)
1 data of
1.1 general data
96 cases of children patients suffering from skin eczema and diagnosed in Jinshan Hospital affiliated to the university of Fudan in 2018, 6-2020 and 5 are selected, and are divided into three groups according to a random digital table method, wherein the three groups are respectively an experimental group, a control group and a control group, before treatment, the children patients in each group have no significant difference in the aspects of sex, age, course of disease and the like, and have good balance among the groups and comparability.
1.2 inclusion criteria
The age is 7d-22 months.
Secondly, the medicine accords with the acute eczema diagnosis standard in skin pathology (published by the national health publisher, 2002) and traditional Chinese medicine syndrome diagnosis curative effect standard issued by the national traditional Chinese medicine administration (published by 1994);
the skin itch area is large and the symptom caused by acute attack of chronic eczema is met;
fourthly, other medicines for treating eczema are not used before.
1.3 criteria for shedding
(1) Incomplete data will affect the final statistical data result.
(2) After inclusion, the false-selected person is found to be not in accordance with the inclusion standard, or the person in accordance with the exclusion standard.
2 method
2.1 methods of treatment
Experimental groups: the traditional Chinese medicine composition in the embodiment 9 is prepared into lotion, the children patients are externally washed for 15-20 minutes twice a day, 2-3 weeks are a treatment course, and the dosage of the medicine is reduced as appropriate for the patients with small eczema.
Control group: applying the pimpines ointment externally for 3 times/d, 7 days for 1 treatment course, and 1 treatment course.
Control two groups: the traditional Chinese medicine composition is used: 25 parts of folium artemisiae argyi, 65 parts of radix sophorae flavescentis, 10 parts of cortex phellodendri, 10 parts of rhizoma atractylodis, 10 parts of oldenlandia diffusa, 15 parts of dendrobe, 5 parts of codonopsis pilosula, 10 parts of radix sileris and 10 parts of gallnut. The lotion is prepared, the children patients are externally washed for 15-20 minutes each time, twice a day, 2-3 weeks are a treatment course, and the dosage of the medicine is reduced as appropriate for the patients with small eczema area.
2.2 therapeutic efficacy assessment criteria
And (3) healing: after a course of treatment; the infiltration liquid is completely absorbed, the erythema and the pimple are completely removed, and the subjective symptoms disappear.
The effect is shown: the exudate is completely absorbed, the erythema and pimple are obviously subsided by more than or equal to 70 percent, and the subjective symptoms are obviously improved.
The method has the following advantages: the exudate is basically absorbed, the erythema is more than or equal to 30 percent, the pimple is less than 80 percent, and the subjective symptoms are relieved.
And (4) invalidation: there was still little exudate, and the erythema and pimple resolved < 30%, even worsened.
3 results
The results of the treatment effect and the recurrence rate of each group are shown in Table 2.
TABLE 2 curative effect and recurrence rate of each group
The children patients are revisited after 3 months without recurrence. The experimental group has significant difference in total effective rate and recurrence rate compared with the control group and the control group.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.
Claims (10)
1. The traditional Chinese medicine composition for treating eczema is characterized by comprising the following raw material medicines in parts by weight: 20-30 parts of folium artemisiae argyi, 30-60 parts of radix sophorae flavescentis, 4-9 parts of mint, 10-15 parts of wild chrysanthemum flower, 9-15 parts of radix stemonae, 9-15 parts of szechwan chinaberry fruit, 12-18 parts of spreading hedyotis herb, 9-15 parts of cortex dictamni, 6-12 parts of duckweed, 6-12 parts of pepper, 12-15 parts of mulberry leaf, 12-15 parts of fructus kochiae, 12-15 parts of honeysuckle flower and 15-30 parts of honeysuckle stem.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 25-30 parts of folium artemisiae argyi, 40-60 parts of radix sophorae flavescentis, 6-9 parts of mint, 12-15 parts of wild chrysanthemum flower, 12-15 parts of radix stemonae, 9-12 parts of szechwan chinaberry fruit, 12-15 parts of spreading hedyotis herb, 12-15 parts of cortex dictamni, 6-10 parts of duckweed, 6-10 parts of pepper, 13-15 parts of mulberry leaf, 13-15 parts of fructus kochiae, 13-15 parts of honeysuckle flower and 25-30 parts of honeysuckle stem.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 30 parts of folium artemisiae argyi, 60 parts of radix sophorae flavescentis, 6 parts of mint, 15 parts of wild chrysanthemum flower, 15 parts of radix stemonae, 9 parts of szechwan chinaberry fruit, 12 parts of spreading hedyotis herb, 15 parts of cortex dictamni, 6 parts of duckweed, 6 parts of pepper, 15 parts of mulberry leaf, 15 parts of fructus kochiae, 15 parts of honeysuckle flower and 30 parts of honeysuckle stem.
4. The Chinese medicinal composition of any one of claims 1-3, wherein the Chinese medicinal composition further comprises a pharmaceutically acceptable carrier.
5. The Chinese medicinal composition according to any one of claims 1 to 3, wherein the Chinese medicinal composition is in a clinically acceptable external preparation.
6. The composition of claim 5, wherein the topical dosage form comprises a spray, a liniment, a paste, a lotion, or a patch.
7. Use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for treating eczema.
8. Use of a Chinese medicinal composition according to any one of claims 1 to 3 for the preparation of a medicament for the treatment of skin pruritus caused by acute eczema and/or acute episode of chronic eczema.
9. Use of the Chinese medicinal composition of any one of claims 1 to 3 for the preparation of a medicament for treating skin itch caused by acute eczema in children and/or acute attack of chronic eczema in children.
10. A lotion for treating eczema, which is prepared from the Chinese medicinal composition of any one of claims 1 to 3, and the preparation method of the lotion comprises the following steps:
(1) taking the raw materials according to the weight part ratio, cleaning, putting into an automatic purple sand traditional Chinese medicine decocting pot, adding water, soaking over strong fire, and decocting for 0.5-1 hour;
(2) decocting with slow fire for 15-20 min;
(3) removing residue, filtering, and decocting in water for 1 time;
(4) mixing the filtrates, and cooling to 38-44 deg.C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110225033.6A CN112755143B (en) | 2021-03-01 | 2021-03-01 | Traditional Chinese medicine composition for treating eczema and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110225033.6A CN112755143B (en) | 2021-03-01 | 2021-03-01 | Traditional Chinese medicine composition for treating eczema and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112755143A true CN112755143A (en) | 2021-05-07 |
CN112755143B CN112755143B (en) | 2022-06-24 |
Family
ID=75704338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110225033.6A Active CN112755143B (en) | 2021-03-01 | 2021-03-01 | Traditional Chinese medicine composition for treating eczema and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112755143B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116763883A (en) * | 2023-07-26 | 2023-09-19 | 黑龙江中医药大学 | Effervescent tablet lotion containing traditional Chinese medicine extract and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102784340A (en) * | 2012-08-09 | 2012-11-21 | 陈俊梅 | Traditional Chinese medicine composition for treating children eczema |
CN103463539A (en) * | 2013-10-11 | 2013-12-25 | 成都中医药大学附属医院 | Drug for treating eczema, and preparation method and use thereof |
CN105687960A (en) * | 2016-03-21 | 2016-06-22 | 廖辉 | Traditional Chinese medicine preparation for preventing infant eczema |
CN106266152A (en) * | 2016-11-07 | 2017-01-04 | 成都中医药大学附属医院 | A kind of pharmaceutical composition treating eczema and its production and use |
CN109568519A (en) * | 2017-09-28 | 2019-04-05 | 北京盈科瑞创新药物研究有限公司 | A kind of Chinese medicine composition and preparation method thereof for eczema |
CN110051806A (en) * | 2019-05-30 | 2019-07-26 | 马爱香 | The Chinese medicinal lotion pharmaceutical formulation for treating infantile eczema |
CN110711223A (en) * | 2019-11-12 | 2020-01-21 | 重庆瑧优堂生物科技有限公司 | Skin-benefiting powder for children |
-
2021
- 2021-03-01 CN CN202110225033.6A patent/CN112755143B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102784340A (en) * | 2012-08-09 | 2012-11-21 | 陈俊梅 | Traditional Chinese medicine composition for treating children eczema |
CN103463539A (en) * | 2013-10-11 | 2013-12-25 | 成都中医药大学附属医院 | Drug for treating eczema, and preparation method and use thereof |
CN105687960A (en) * | 2016-03-21 | 2016-06-22 | 廖辉 | Traditional Chinese medicine preparation for preventing infant eczema |
CN106266152A (en) * | 2016-11-07 | 2017-01-04 | 成都中医药大学附属医院 | A kind of pharmaceutical composition treating eczema and its production and use |
CN109568519A (en) * | 2017-09-28 | 2019-04-05 | 北京盈科瑞创新药物研究有限公司 | A kind of Chinese medicine composition and preparation method thereof for eczema |
CN110051806A (en) * | 2019-05-30 | 2019-07-26 | 马爱香 | The Chinese medicinal lotion pharmaceutical formulation for treating infantile eczema |
CN110711223A (en) * | 2019-11-12 | 2020-01-21 | 重庆瑧优堂生物科技有限公司 | Skin-benefiting powder for children |
Non-Patent Citations (2)
Title |
---|
杨慧敏等: "皮肤瘙痒的发生机理与中医辨证施治相关性探讨", 《中国中西医结合皮肤性病学杂志》 * |
覃永健等: "急性湿疹外洗方组方规律探讨", 《中医外治杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116763883A (en) * | 2023-07-26 | 2023-09-19 | 黑龙江中医药大学 | Effervescent tablet lotion containing traditional Chinese medicine extract and preparation method thereof |
CN116763883B (en) * | 2023-07-26 | 2024-04-09 | 黑龙江中医药大学 | Effervescent tablet lotion containing traditional Chinese medicine extract and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112755143B (en) | 2022-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101445010B1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof | |
JP2018508503A (en) | Acne-removing skin care products and methods for their production | |
CN108272862B (en) | Pudilan oral spray and preparation method thereof | |
CN101062289A (en) | External application medicine combination for treating gout | |
KR20180073437A (en) | A cosmetic composition comprising a mixture of natural herbs extracts | |
CN104920772A (en) | Tooth decay preventing chewing gum and a preparation method thereof | |
KR101474125B1 (en) | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia | |
CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
CN112755143B (en) | Traditional Chinese medicine composition for treating eczema and application thereof | |
KR20140097095A (en) | Composition for promoting the volume of skin | |
CN104474028B (en) | Ointment for the treatment of skin pruritus and preparation method thereof | |
CN104873446A (en) | Cinnamon oil containing toothpaste | |
CN111803567A (en) | Camellia oil antibacterial and anti-inflammatory gel and preparation method thereof | |
CN106963912B (en) | Dalbergia wood compound composition for treating eczema and preparation method thereof | |
CN113616774B (en) | Antibacterial composition containing plant stem cells, maintenance antibacterial liquid and preparation method thereof | |
CN100502906C (en) | External-applied ointment of skin tinea and preparation thereof | |
CN101890100B (en) | Medicament for curing dermatitis and eczema and preparation method thereof | |
CN103920124B (en) | A kind of sterilizing skin-protective kibe ointment | |
CN103860977B (en) | A kind of pharmaceutical composition for the treatment of dermatitis | |
CN102772644A (en) | Traditional Chinese medicine composition and preparation with detumescence repairing function and preparation method thereof | |
CN105343847A (en) | Traditional Chinese medicine composition for treating eczema containing folium artemisiae argyi and preparing method thereof | |
CN105456708B (en) | Medicine for treating cheilitis and preparation method thereof | |
CN107569580B (en) | A topical Chinese medicinal composition for treating hemorrhoid, and its preparation method | |
CN111686165A (en) | Pure traditional Chinese medicine composition for relieving itching of private parts, preparation and application of pure traditional Chinese medicine composition in cleaning private parts | |
CN101953951B (en) | Hand and feed health-care and beautifying liquid and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |